Jumawan, Julie D.

HRN: 22-27-78  Sex: Female

Patient Encounter


Audit Details

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
02/06/2023
CEFAZOLIN 1GM (VIAL)
02/06/2023
02/13/2023
IV
1g
Q8hrs
Giant Cell Tumor Distal 3rd Femur Right
Waiting Final Action 

Indication:  Empiric    Type of Infection:  Skin & Soft Tissue    Compliance to guidelines: Compliant To Guidelines

Initial appropriateness: Yes   

Final appropriateness: Yes   

Overall appropriateness: Yes 

Intervention



Type of Intervention done:

                    

           


Acceptance: